# HIF2α inhibits glutaminase clustering in mitochondria to sustain growth of clear cell renal cell carcinoma

## TL;DR

A cancer-driving protein prevents glutaminase clustering in kidney tumors, offering a new treatment strategy.

## Contribution

Discovery that HIF2α suppresses GLS1 clustering to sustain ccRCC growth, revealing a novel therapeutic mechanism.

## Key findings

- GLS1 clustering in mitochondria increases glutaminase activity and induces cell death under glutamine deprivation.
- HIF2α prevents GLS1 clustering, maintaining low GLS activity and protecting ccRCC cells.
- Forced GLS1 clustering promotes apoptosis and suppresses tumor growth in vivo.

## Abstract

Clear cell renal cell carcinomas (ccRCCs) are largely driven by HIF2α and are avid consumers of glutamine. However, inhibitors of glutaminase 1 (GLS1), the first step in glutaminolysis, have not shown benefit in phase III trials, and HIF2α inhibition, recently FDA approved for treatment of ccRCC, shows significant but incomplete benefits. This highlights the need to better understand the interplay between glutamine metabolism and HIF2α in ccRCC. Here, we report that glutamine deprivation rapidly redistributed GLS1 into isolated clusters within mitochondria in diverse cell types, but not in ccRCC. GLS1 clustering occurred rapidly within 1–3 hours, was reversible, was specifically triggered by reduced intracellular glutamate, and was dependent on mitochondrial fission. Clustered GLS1 markedly enhanced glutaminase activity and promoted cell death under glutamine-deprived conditions. HIF2α prevented GLS1 clustering, independently of its transcriptional activity, thereby maintaining low GLS activity and protecting ccRCC cells from glutamine-deprivation-induced cell death. Forced clustering of GLS1, using constitutively clustering mutants, restored high GLS activity, promoted apoptosis, and suppressed ccRCC tumor growth in vivo. These findings reveal multiple insights into cellular glutamine handling, including a previously unrecognized process by which HIF2α promotes ccRCC: by suppressing GLS1 clustering and maintaining low GLS activity. This mechanism provides a potential explanation for the lack of clinical efficacy of GLS inhibitors in ccRCC and suggests a therapeutic avenue to combine HIF2α inhibition with strategies that restore GLS1 clustering.

The cancer-driving protein HIF2α blocks clustering and activation of glutaminase, allowing kidney tumor cells to keep growing and revealing a new therapeutic target.